S&P 500 Healthcare Sector SEC Filings — June 12, 2026

EVP & Chief TO and Risk Officer sold $2.41M of stock at $241.15, exercising options at $115.67 for a $1.25M profit. This large insider sale by a top risk officer could signal concern about valuation or near-term risks, though it was part of a pre-arranged plan.

Director sold $60.7K of stock at $401.77, a relatively small transaction but the only insider activity for the company. The sale reduces his holdings to 10,734 shares.

EVP sold $19.9K total under a 10b5-1 plan, a minimal amount relative to the company's market cap. The pre-planned nature reduces bearish signal strength.

The insider exercised 10,000 options at $115.67 and immediately sold at $241.15, realizing a $1.25M gain. This is a classic cash-out move, often viewed as a lack of conviction in further upside.

The director's sale at $401.77 comes at a price near recent levels, with no insider buying to offset the selling pressure.

The EVP's sale of only 48 shares total (23+25) is negligible and likely part of routine tax withholding or plan execution, not a strategic signal.

The EVP & Chief TO and Risk Officer sold 100% of the options exercised, converting them to cash. This is a red flag for risk management oversight, as the company's top risk officer is reducing exposure.

The director sold 151 shares, representing a small portion of holdings but the only insider transaction. Lack of buying from other insiders adds to concern.

While small, the EVP sold shares under a 10b5-1 plan, which could indicate a pre-planned diversification strategy. No insider buying to counterbalance.

After the sale, the officer still holds 114,287 shares (~$27.5M), but the decision to cash out $2.41M is notable for a risk officer.

No insider buying, no positive guidance, and no capital allocation announcements (dividends, buybacks) in any of the three filings. This creates a uniformly cautious tone.

The sale occurred on June 12, 2026, with no forward-looking statements in the filing to justify the move. Investors should watch for any subsequent negative news or guidance cuts.

The $2.41M insider sale at $241.15 may create a short-term dip, offering a buying opportunity for long-term investors if the company's fundamentals remain strong. JNJ's diversified healthcare portfolio and dividend yield provide a margin of safety.

The director's small sale ($60.7K) is likely insignificant relative to the company's $100B+ market cap. If the stock dips, it could be a buying opportunity for value investors.

The filing explicitly states the trades were under a Rule 10b5-1 plan, reducing negative signaling. This transparency can be seen as a positive governance signal.

The exercise price of $115.67 shows the insider had deep in-the-money options, suggesting long-term confidence in the company's performance. The sale may simply be portfolio diversification.

The lack of period-over-period data or guidance in these filings means the next earnings reports (likely July 2026) will be critical. Investors can use this quiet period to build positions before catalysts.

As a leading health insurer, Elevance may benefit from upcoming Medicare Advantage enrollment changes. The insider sale is too small to alter the investment thesis.

All three filings (100%) reported insider selling with no buying, indicating a cautious stance among executives. This could reflect sector-wide concerns about regulatory headwinds or valuation.

Two of the three sales (J&J and Intuitive Surgical) were under pre-arranged plans, suggesting the selling may not reflect current sentiment. This is a common practice in the healthcare sector for executives to diversify.

None of the filings contained period-over-period comparisons, forward-looking guidance, or capital allocation changes. This highlights the need for investors to wait for quarterly earnings for substantive insights.

Despite sales, insiders at J&J and Elevance still hold significant positions ($27.5M and $4.3M respectively), indicating ongoing alignment with shareholders.

Monitor for any additional insider sales by other C-suite executives, especially the CEO or CFO, which could confirm a broader bearish trend. Next earnings call expected mid-July 2026.

Watch for any insider buying by directors or executives to offset the recent sale. Also monitor for Medicare Advantage rate announcements that could impact the stock.

Track the EVP's future 10b5-1 plan transactions. If selling accelerates, it could signal deeper concerns. Next earnings call expected late July 2026.

Monitor for any Form 8-K filings with material events (e.g., guidance changes, M&A, regulatory decisions) that could explain the insider selling pattern.

The risk officer's sale is particularly noteworthy. Watch for any risk-related disclosures in the next 10-Q or 8-K that might have prompted the sale.

The director's sale at $401.77 is near the stock's 52-week range. A break below $400 could trigger further selling or present a buying opportunity.

The stock trades at a high P/E multiple. Any insider selling, even small, could be amplified by market sentiment. Monitor for any competitive or regulatory news in the robotic surgery space.